GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Operating Margin %

Neuraxis (Neuraxis) Operating Margin % : -283.15% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Neuraxis's Operating Income for the three months ended in Mar. 2024 was $-1.83 Mil. Neuraxis's Revenue for the three months ended in Mar. 2024 was $0.65 Mil. Therefore, Neuraxis's Operating Margin % for the quarter that ended in Mar. 2024 was -283.15%.

The historical rank and industry rank for Neuraxis's Operating Margin % or its related term are showing as below:

NRXS' s Operating Margin % Range Over the Past 10 Years
Min: -330.07   Med: -169.56   Max: -109.15
Current: -330.07


NRXS's Operating Margin % is ranked worse than
59.06% of 1026 companies
in the Biotechnology industry
Industry Median: -158.97 vs NRXS: -330.07

Neuraxis's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Neuraxis's Operating Income for the three months ended in Mar. 2024 was $-1.83 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.60 Mil.


Neuraxis Operating Margin % Historical Data

The historical data trend for Neuraxis's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis Operating Margin % Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Operating Margin %
-213.52 -109.15 -125.59 -270.89

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -111.30 -173.07 -633.54 -305.65 -283.15

Competitive Comparison of Neuraxis's Operating Margin %

For the Biotechnology subindustry, Neuraxis's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuraxis's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Neuraxis's Operating Margin % falls into.



Neuraxis Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Neuraxis's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-6.664 / 2.46
=-270.89 %

Neuraxis's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-1.832 / 0.647
=-283.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuraxis  (AMEX:NRXS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Neuraxis Operating Margin % Related Terms

Thank you for viewing the detailed overview of Neuraxis's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuraxis (Neuraxis) Business Description

Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042